1
H index
0
i10 index
6
Citations
Grace Hampson : Citation Profile
Office of Health Economics | RESEARCH PRODUCTION: 4 Articles 15 Papers RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
4 years (2015 - 2019). Relations with other researchers
Works with:
Authors registered in RePEc who have co-authored more than one work in the last five years with Grace Hampson. | Is cited by:
| Cites to:
|
Main data
Where Grace Hampson has published?
| Working Papers Series with more than one paper published | # docs |
|---|---|
| Research Papers / Office of Health Economics | 7 |
| Consulting Reports / Office of Health Economics | 4 |
| Briefings / Office of Health Economics | 4 |
Recent works citing Grace Hampson (2019 and 2018)
| Year | Title of citing document |
|---|---|
| 2018 | Funding breakthrough therapies: A systematic review and recommendation. (2018). Hanna, E ; Auquier, P ; Badora, K ; Dabbous, O ; Borissov, B ; Dussart, C ; Toumi, M. In: Health Policy. RePEc:eee:hepoli:v:122:y:2018:i:3:p:217-229. Full description at Econpapers || Download paper |
| 2019 | Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance. (2019). Crispi, Francisca ; Mossialos, Elias ; Osipenko, Leeza ; Barkauskaite, Eva ; Naci, Huseyin. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:17:y:2019:i:2:d:10.1007_s40258-018-0438-y. Full description at Econpapers || Download paper |
| 2018 | The Future of Precision Medicine: Potential Impacts for Health Technology Assessment. (2018). Love-Koh, James ; Taylor, Matthew ; Wood, Hannah ; Chalkidou, Anastasia ; Manca, Andrea ; Lovett, Rosemary ; Ennis, Kate ; Rejon-Parrilla, Juan Carlos ; Peel, Alison. In: PharmacoEconomics. RePEc:spr:pharme:v:36:y:2018:i:12:d:10.1007_s40273-018-0686-6. Full description at Econpapers || Download paper |
| 2018 | Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?. (2018). Mestre-Ferrandiz, Jorge ; Hidalgo-Vega, alvaro ; Alcala, Bleric ; Zozaya, Neboa . In: PharmacoEconomics. RePEc:spr:pharme:v:36:y:2018:i:12:d:10.1007_s40273-018-0716-4. Full description at Econpapers || Download paper |
| 2018 | The Impact of Brexit on Pharmaceuticals and HTA. (2018). Lorgelly, Paula. In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:2:y:2018:i:2:d:10.1007_s41669-018-0072-5. Full description at Econpapers || Download paper |
Works by Grace Hampson:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2016 | New Age Decision Making in HTA: Is It Applicable in Asia? In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2017 | How can HTA meet the needs of health system and government decision makers? In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Transferability of HTA In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2016 | Four Case Studies to Explore the Added Value of Oxford AHSN In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose? In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
| 2019 | Public Preferences for Health Gains and Cures: A Discrete Choice Experiment In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2015 | Dementia: The R&D Landscape In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2016 | A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications In: Research Papers. [Full Text][Citation analysis] | paper | 1 |
| 2016 | Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2018 | Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).(2018) In: PharmacoEconomics - Open. [Full Text][Citation analysis] This paper has another version. Agregated cites: 0 | article | |
| 2017 | Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value In: Research Papers. [Full Text][Citation analysis] | paper | 1 |
| 2017 | Macro Evaluation of the NIHR Oxford Biomedical Research Centre In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2018 | Real World Evidence for Coverage Decisions: Opportunities and Challenges In: Research Papers. [Full Text][Citation analysis] | paper | 1 |
| 2018 | Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2017 | What Determines the Health Care Expenditure of High Income Countries? A Dynamic Estimation In: Applied Economics and Finance. [Full Text][Citation analysis] | article | 0 |
| 2017 | A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact? In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 2 |
| 2019 | Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 0 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated November, 11 2019. Contact: CitEc Team